Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
The CDC issued a report that supports earlier findings, stating that the efficacy of this year's flu vaccine is low.
Researchers associated with the Mount Sinai Health System believe that a universal flu vaccine could be closer to development.
The U.S. Food and Drug Administration (FDA) has approved RAPIVAB, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older.
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
The Centers for Disease Control and Prevention (CDC) issued a health warning about the current flu vaccine.
Those same experts report the flu vaccine is safe for patients who have not had a stem cell transplant.
People with weakened immune systems due to cancer are at increased risk of severe complications from the influenza virus, according to experts.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|